First-of-its-Kind cell therapy trial aims to reset immune system in devastating nerve disorders
NCT ID NCT07304154
Summary
This early-stage study is testing a new personalized cell therapy called KITE-363 for people with severe autoimmune nerve diseases that haven't responded to standard treatments. The therapy involves modifying a patient's own immune cells to target and remove harmful B cells that drive these diseases. The main goals are to find a safe dose and see if it can help control conditions like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.